This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07710729 |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 40 participants |
| Design | Interventional, Non Randomized, Sequential, Masking: None |
| Conditions | Overweight; Obesity |
| Interventions | UBT251; Oral contraceptive; Acetaminophen |
| Start | Jul 17, 2026 |
| Primary completion | Apr 27, 2027 |
| Study completion | Apr 27, 2027 |
| Results posted | Not yet |
| Registry last updated | Aug 25, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like birth control tablets, and emptying of the stomach in women not able to become pregnant living with overweight or obesity
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| AUC,EE,SS: The area under the EE plasma concentration time curve during a dosing interval at steady state | From pre-dose on Day 8 up to 157 days |
| AUC ,LN,SS: The area under the LN plasma concentration time curve during a dosing interval at steady state | From pre-dose on Day 8 up to 157 days |
4 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UBT251 Phase 3 in Overweight or Obesity (China) (Phase 3 NCT07648225)
- UBT251 Safety, Tolerability and Efficacy in Overweight or Obesity (Novo Nordisk Phase 2) (Phase 2 NCT07395687)
- UBT251 Injection Phase II Clinical Study (CKD) (Phase 2 NCT07134335)
- UBT251 Injection Phase II Study (Overweight or Obesity) (Phase 2 NCT07177469)
- A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood (Phase 1 NCT07710768)
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
